The EPO published patent application EP3699192A2 on March 25, 2026, for Green Cross Corporation and Mogam Institute for Biomedical Research. The patent covers anti-CD3 antibodies and pharmaceutical compositions for cancer treatment (A61P 35/00), classified under C07K 16/28. The application designates 38 European states including all EU member states and additional European Economic Area countries.

This publication represents a patent grant establishing intellectual property rights for the applicants in designated European markets. No compliance deadlines, required actions, or penalties apply to third parties. Competitors developing similar immunotherapeutic antibodies should review the patent claims for potential licensing needs or design-around considerations.